title: Dramatic complete response in patient with lung adenocarcinoma.
abstract: The poor prognosis of non-small-cell lung cancer (NSCLC) is changing thanks to the constant development of new treatments and the introduction of target therapies, even in stage IV disease. This patient had bone metastases when he was diagnosed. Maintenance treatment, a much discussed topic nowadays, achieved a dramatic complete response.
authors.affiliation: Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. sarusky_zgz@hotmail.com
authors.forename: Sara
authors.initials: S
authors.lastname: Serrano Solares
authors.forename: Dolores
authors.initials: D
authors.lastname: Isla Casado
authors.forename: María Jesús
authors.initials: MJ
authors.lastname: Vidal Losada
authors.forename: María
authors.initials: M
authors.lastname: Tobeña Puyal
authors.forename: Ana Isabel
authors.initials: AI
authors.lastname: Ferrer Pérez
authors.forename: Isabel
authors.initials: I
authors.lastname: Pajares
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab